Cardio Diagnostics Holdings Inc logo

Cardio Diagnostics Holdings Inc(CDIO)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.71
11/17/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CDIO

11/17/2026: CDIO (1-star) is currently NOT-A-BUY. Pass it for now.

Cardio Diagnostics Holdings Inc is a micro-cap medical technology company specializing in AI-driven, epigenetics-based clinical blood tests for cardiovascular disease. The company's primary operational strengths include its innovative multi-omics engine, proprietary tests like Epi+Gen CHD, and newly established in-house CLIA-certified laboratory capabilities. Its core investment story centers on capturing market share within preventative cardiology through provider network expansion and telehealth integrations. However, the company faces substantial risks, including very limited commercial revenue, persistent net losses, high share price volatility, and intense competition from larger diagnostic incumbents. The stock is best suited for speculative or risk-tolerant investors who should closely monitor test adoption rates, reimbursement progress, and capital preservation.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high-growth potential in precision medicine, but currently lacks the scaled revenue stream required for traditional growth mandates.
Momentum investorStrong fit while signal remains positiveMicro-cap status and low float can lead to sharp short-term price movements upon positive clinical or commercial news.
Value investorWeak fitOngoing operational losses and negative earnings preclude traditional fundamental value investing metrics.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for business development.
Low-risk investorWeak fitHigh share price volatility, micro-cap liquidity risks, and pre-profit financials present substantial risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow market capitalization and trading volume cause sharp daily percentage price swings.
Valuation riskHighValuation relies heavily on future commercial execution rather than current earnings or tangible asset backing.
Competition risk (molecular diagnostics competition)Medium / highWell-funded diagnostic giants dominate laboratory testing channels and provider relationships.
Business qualityMediumProprietary AI multi-omics science is innovative, but commercial validation is still at an early stage.
Dividend incomeLow / noneNo dividends are paid or anticipated in the near term.
Execution riskHighSuccess depends on physician adoption, scaling laboratory throughput, and obtaining favorable insurance reimbursement.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 5.06M USD
Price to earnings Ratio -
1Y Target Price 60
Price to earnings Ratio -
1Y Target Price 60
Volume (30-day avg) 22.1K shares
Beta 2.27
52 Weeks Range 0.97 - 7.91
Updated Date 11/17/2026
52 Weeks Range 0.97 - 7.91
Updated Date 11/17/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.52

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
62.3%
Active BUY / eligible
66 / 106
30-Day BUY Count Change
+23
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.6%
Active BUY / eligible
17 / 39
30-Day BUY Count Change
+10

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -60.09%
Avg. Invested days 7
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/17/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CDIO receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
CDIO has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and moderate ownership. In FY2025 versus FY2024, solid earnings growth (+22.5%) is partially offset by weak cash generation (FCF margin -39893.1%), negative revenue growth (-57.5%), weak profitability (net margin -43832.5%).

Financial Health Rating

★★★★★
CDIO's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 68.4%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is CDIO's strongest growth driver at +22.5% FY2025 versus FY2024 (solid, 4 stars). By comparison, while revenue growth (-57.5%, negative) and free-cash-flow growth (-9.6%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 6.8% (soft) and 95.8% of outstanding shares are publicly tradable (strong). Insider ownership of 8.31% supports management-shareholder alignment.

Top 5 Institutional Investors

Renaissance Technologies Corp 1.59%
BlackRock Inc 1.17%
Geode Capital Management, LLC 0.89%
Vanguard Capital Management, LLC 0.68%
Citadel Advisors Llc 0.64%

Unit Economics (Per $1K Revenue)

★★★★★
CDIO generates approximately $1,000 of gross profit, $-437,375 of operating income, and $-398,931 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
CDIO has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Testing ServicesProcessing and delivering results for proprietary molecular blood tests such as Epi+Gen CHD and PrecisionCHD.The company generates core revenue when healthcare providers order its specialized cardiovascular tests.
Intelligence Platforms & Software-as-a-Service (SaaS)Subscription and access fees for HeartRisk and Actionable Clinical Intelligence platforms utilized by providers and employers.Provides recurring software technology revenue streams alongside physical test processing.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1.59M
Price to Sales(TTM) 333.27
Enterprise Value 1.59M
Price to Sales(TTM) 333.27
Enterprise Value to Revenue 104.94
Enterprise Value to EBITDA -22.48
Shares Outstanding 2.96M
Shares Floating 2.84M
Shares Outstanding 2.96M
Shares Floating 2.84M
Percent Insiders 8.31
Percent Institutions 6.77

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.